KRAS Inhibitor Daraxonrasib Shows Promise in Pancreatic Cancer
Revolution Medicines' daraxonrasib shows meaningful responses in KRAS-mutant pancreatic cancer in Phase 2 data, marking a breakthrough in a notoriously hard-to-treat disease.
Oncology Drug Development
2 articles tagged "Oncology Drug Development"
Pancreatic Cancer Pill Doubles Survival in New Trial
Revolution Medicines' daraxonrasib nearly doubled median survival in metastatic pancreatic cancer patients compared to chemotherapy, according to new data.